Versartis Announces Positive 12 Month Data for VRS-317 from Ongoing Extension Study Successful Dose Response Further Confirms Phase 3 Trial Design Company to Hold Conference Call at 8:30 a.m. ET on Monday, January 5, 2015 MENLO PARK, Calif., Jan. 5, 2015 /PRNewswire/...
Relypsa Announces Assignment of October 21, 2015 PDUFA Date for New Drug Application for Patiromer for Oral Suspension FDA Not Currently Planning to Hold an Advisory Committee Meeting Company to Host Webcasted Analyst Day in New York on January 8, 2015 REDWOOD CITY,...
Oxford Immunotec Announces Completion of Re-Registration in China for T-SPOT.TB Test OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 6, 2015 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused...
Biogen Idec to Expand Neuropathic Pain Portfolio with the Acquisition of Convergence Pharmaceuticals CAMBRIDGE, Mass. — January 11, 2015 — Biogen Idec (NASDAQ: BIIB) announced today that it has agreed to acquire U.K.-based Convergence Pharmaceuticals, a...
Chimerix Receives Notice of Allowance for Brincidofovir Composition of Matter Patent Extending Exclusivity to 2034 Opportunity to pursue multiple additional indications for brincidofovir DURHAM, N.C., Jan. 12, 2015 (GLOBE NEWSWIRE) — Chimerix, Inc....
Recent Comments